News

Drug Reimbursement Recommendation - Nerlynx, Tecentriq and Lynparza

Today, CADTH has issued final recommendations for:

Nerlynx for Hormone Receptor-Positive Breast Cancer

Funding Request: For patients with HER2-positive, hormone receptor-positive breast (HR-positive) cancer who have completed adjuvant trastuzumab-based therapy within the past 12 months.
Recommendation: Do not reimburse
Notification to implement target date: December 20, 2019

For more information

Tecentriq for Small Cell Lung Cancer

Funding Request: For the first-line treatment of patients with extensive stage small cell lung cancer (ES-SCLC) in combination with a platinum-based chemotherapy and etoposide. Maintenance TECENTRIQ should be continued until loss of clinical benefit or unacceptable toxicity.
Recommendation: Do not reimburse
Notification to implement target date: December 20, 2019

For more information

Lynparza for Newly Diagnosed Ovarian Cancer

Funding Request: As monotherapy for the maintenance treatment of adult patients with newly diagnosed advanced BRCA-mutated high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete response or partial response) to first-line platinum-based chemotherapy, until disease progression or up to 2 years if no evidence of disease. Patients must have confirmation of BRCA mutation (identified by either germline or tumour testing) before LYNPARZA treatment is initiated.
Recommendation: Reimburse with clinical criteria and/or conditions
Notification to implement target date: December 20, 2019

For more information